Developing vaccines that work with the body's natural bacteria
Building the foundations of commensal vaccines
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-10904883
This study is looking at new types of vaccines that use helpful bacteria in our bodies to boost our immune system against diseases like cancer and autoimmune disorders, making it easier for everyone to get better protection without relying on traditional vaccine methods.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10904883 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative vaccines that leverage the body's microbiome to enhance immune responses against diseases like cancer and autoimmune disorders. By utilizing specific bacterial strains, the project aims to generate strong and lasting immunity without the need for traditional vaccine delivery methods. This approach seeks to overcome the limitations of current therapies, such as the ineffectiveness of some treatments in certain patients and the challenges of vaccine distribution in low-resource settings. The research will explore how these bacterial interactions can be harnessed to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with acute lymphoblastic leukemia, autoimmune diseases, or those at risk for infectious diseases.
Not a fit: Patients who do not have immune-related conditions or those who are not responsive to immune modulation therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and accessible vaccines that improve immune responses in patients with various conditions.
How similar studies have performed: Previous research has shown promise in using microbiome interactions to enhance immune responses, suggesting that this approach could be a significant advancement in vaccine development.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FISCHBACH, MICHAEL ANDREW — STANFORD UNIVERSITY
- Study coordinator: FISCHBACH, MICHAEL ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases